Top

Published in:

20-09-2022 | Vasculitis | Letter to the Editor

New-onset eosinophilic granulomatosis with polyangiitis in 2 patients during treatment with IL-5 pathway inhibitors

Authors: Jan Holubar, Erik Arnaud, Jonathan Broner, Yves-Marie Pers, Alain Proust, Radjiv Goulabchand

Published in: Immunologic Research | Issue 6/2022

Excerpt

We would like to report two cases of eosinophilic granulomatosis with polyangiitis (EGPA) emergence in patients treated with interleukin 5 pathway inhibitors (IL-5(R)). Such occurrence has only been published twice previously [1, 2]. Our series adds to the literature with a comprehensive description of EGPA cases under anti-IL-5(R) inhibitor exposure, leading to original immunological hypotheses. …

Hočevar A, Kopač P, Rotar Ž, Novljan MP, Škrgat S. Eosinophilic granulomatosis with polyangiitis evolution during severe eosinophilic asthma treatment with benralizumab. J Allergy Clin Immunol Pract. 2020;8:2448–9. https://doi.org/10.1016/j.jaip.2020.04.006.CrossRefPubMed

Caminati M, Maule M, Nalin F, Senna G, Lunardi C. Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma. Rheumatol Oxf Engl. 2021;60:e59-60. https://doi.org/10.1093/rheumatology/keaa572.CrossRef

Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376:1921–32. https://doi.org/10.1056/NEJMoa1702079.CrossRefPubMedPubMedCentral

Alessandra Vultaggio FN. Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis. Allergy Asthma Immunol Res. 2020;12:885. https://doi.org/10.4168/aair.2020.12.5.885.CrossRefPubMedPubMedCentral

Guntur VP, Manka LA, Denson JL, Dunn RM, Dollin YT, Gill M, et al. Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 2021;9:1186-93.e1. https://doi.org/10.1016/j.jaip.2020.09.054.CrossRefPubMed

Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094–100. https://doi.org/10.1002/art.1780330806.CrossRefPubMed

Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81:309–14. https://doi.org/10.1136/annrheumdis-2021-221794.CrossRefPubMed

Canzian A, Venhoff N, Urban ML, Sartorelli S, Ruppert A-M, Groh M, et al. Use of biologics to treat relapsing and/or refractory eosinophilic granulomatosis with polyangiitis: data from a European Collaborative Study. Arthritis Rheumatol Hoboken NJ. 2021;73:498–503. https://doi.org/10.1002/art.41534.CrossRef

Fagni F, Bello F, Emmi G. Eosinophilic granulomatosis with polyangiitis: dissecting the pathophysiology. Front Med. 2021;8: 627776. https://doi.org/10.3389/fmed.2021.627776.CrossRef

10.

Lyons PA, Peters JE, Alberici F, Liley J, Coulson RMR, Astle W, et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun. 2019;10:5120. https://doi.org/10.1038/s41467-019-12515-9.CrossRefPubMedPubMedCentral

11.

Manka LA, Guntur VP, Denson JL, Dunn RM, Dollin YT, Strand MJ, et al. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2021;126:696-701.e1. https://doi.org/10.1016/j.anai.2021.01.035.CrossRef

12.

Ueno M, Miyagawa I, Nakano K, Iwata S, Hanami K, Fukuyo S, et al. Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis. Arthritis Res Ther. 2021;23. https://doi.org/10.1186/s13075-021-02462-6.

13.

Li W, Huang H, Cai M, Yuan T, Sheng Y. Antineutrophil cytoplasmic antibody-associated vasculitis update: genetic pathogenesis. Front Immunol. 2021. https://doi.org/10.3389/fimmu.2021.624848.

Title: New-onset eosinophilic granulomatosis with polyangiitis in 2 patients during treatment with IL-5 pathway inhibitors
Authors: Jan Holubar
Erik Arnaud
Jonathan Broner
Yves-Marie Pers
Alain Proust
Radjiv Goulabchand
Publication date: 20-09-2022
Publisher: Springer US
Keywords: Vasculitis
Vasculitis
Neuropathic Pain
Churg-Strauss Syndrome
Churg-Strauss Syndrome
Glucocorticoid
Bronchial Asthma
Mepolizumab
Published in: Immunologic Research / Issue 6/2022
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-022-09317-5

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

New-onset eosinophilic granulomatosis with polyangiitis in 2 patients during treatment with IL-5 pathway inhibitors

Excerpt

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2022

Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity

Correction to: Human placental extract attenuates neurological symptoms in the experimental autoimmune encephalomyelitis model of multiple sclerosis-a putative approach in MS disease?

Somatic hypermutation defects in two adult hyper immunoglobulin M patients

The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphoma

The predictive potential of autoimmune-inflammatory syndrome induced by adjuvants (ASIA) criteria to assess the risk of adverse events and efficacy of immune checkpoint inhibitor therapy

The effect of the BNT162b2 vaccine on antinuclear antibody and antiphospholipid antibody levels